Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avanos Medical, Inc. filings document the regulatory record of a medical technology company with product portfolios in Specialty Nutrition Systems and Pain Management and Recovery. Current reports furnish operating results, segment performance, investor presentations, material definitive agreements, executive compensation actions and organizational restructuring disclosures.
Proxy materials describe annual meeting matters, board elections, governance practices and compensation programs. The filings also cover capital-structure disclosures, shareholder voting matters, product-portfolio descriptions for enteral feeding and non-opioid pain therapies, and formal exhibits tied to material events.
Avanos Medical, Inc. is asking stockholders to approve a merger under which each issued and outstanding share of Common Stock will be converted into the right to receive $25.00 per share in cash at the effective time of the merger. The transaction agreement was signed on April 13, 2026 and the special meeting to vote is scheduled for July 22, 2026.
The merger is subject to the affirmative vote of a majority of outstanding shares, required regulatory approvals (including HSR and specific foreign authorities), customary closing conditions, and other closing deliverables; the company currently anticipates completion in the second half of 2026.
Avanos Medical, Inc. has entered into a definitive merger agreement under which A-AV MergerSub, affiliated with American Industrial Partners, will merge into Avanos and Avanos will become a wholly‑owned subsidiary of Parent. At the Effective Time, each issued and outstanding share of Avanos common stock (other than treasury shares and perfected appraisal shares) will be cancelled and converted into the right to receive $25.00 in cash per share. The Company currently anticipates completing the Merger in the second half of 2026, subject to Company stockholder approval, required regulatory approvals (including HSR and approvals from specified foreign authorities), and other customary closing conditions. The financing package described contemplates approximately $1.42 billion of total Required Amounts, including an $1.4 billion equity commitment from an AIP‑affiliated fund. The Board unanimously recommends that stockholders vote "FOR" the Merger Proposal, the Advisory Compensation Proposal and the Adjournment Proposal.
Avanos Medical, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,000,000 shares of common stock, representing 4.30% of the class. The filing states Armistice Capital, as investment manager to the Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over those shares. The Master Fund is the direct holder and disclaims direct beneficial ownership due to its investment management agreement with Armistice Capital. The joint filing is signed by Steven Boyd on May 15, 2026.
BLACKFORD GARY reported acquisition or exercise transactions in this Form 4 filing.
AVANOS MEDICAL, INC. director Gary Blackford received a grant of 12,003 restricted share units on May 8, 2026. Each unit represents a contingent right to a cash payment equal to the value of one share of Avanos common stock.
The 12,003 restricted share units were issued to replace units originally granted on January 2, 2025 and will vest when Blackford terminates his service on the company’s Board of Directors.
Egbuonu-Davis Lisa reported acquisition or exercise transactions in this Form 4 filing.
Avanos Medical, Inc. director Lisa Egbuonu-Davis received a grant of 12,003 restricted share units on May 8, 2026. Each unit provides a contingent right to a cash payment equal to the value of one share of Avanos common stock.
The new restricted share units fully replace an earlier grant made on January 2, 2025. These units vest when Egbuonu-Davis terminates her service on the company’s Board of Directors. After this grant, she holds 12,003 restricted share units directly as reported in this filing.
Franchini Indrani Lall reported acquisition or exercise transactions in this Form 4 filing.
Avanos Medical director Indrani Lall Franchini received a grant of 12,003 restricted share units on May 8, 2026. These units are a cash-settled award, each representing a contingent right to receive a payment equal to the value of one share of Avanos common stock.
The new 12,003 restricted share units replace a prior grant originally issued on January 2, 2025. The units vest when Franchini terminates her service on Avanos Medical’s Board of Directors, aligning the award with her continued board tenure rather than short-term performance.
OLEARY PATRICK J reported acquisition or exercise transactions in this Form 4 filing.
AVANOS MEDICAL, INC. director Patrick J. O’Leary received a grant of 12,003 restricted share units on May 8, 2026 as compensation. Each unit represents a contingent right to a cash payment equal to the value of one share of Avanos common stock.
These units were issued to replace restricted share units originally granted on January 2, 2025. The award vests when O’Leary’s service on the company’s Board of Directors ends, meaning the units are long-term, service-based compensation rather than an immediate cash payout.
Shimer Julie Ann reported acquisition or exercise transactions in this Form 4 filing.
AVANOS MEDICAL, INC. director Julie Ann Shimer reported a compensation-related grant of 12,003 restricted share units on May 8, 2026. Each unit is a contingent right to receive a cash payment equal to the value of one share of Avanos common stock.
These restricted share units were issued to replace units originally granted on January 2, 2025, and will vest when Shimer terminates her service on the company’s Board of Directors. Following this award, she holds 12,003 restricted share units directly.
T. Rowe Price Investment Management, Inc. filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership of 1,703,510 shares of Avanos Medical Inc. common stock, representing 3.7% of the class as of 04/30/2026. The filer states it owns 5% or less and disclaims beneficial ownership in the filing.
Avanos Medical Inc. ownership update: T. Rowe Price Investment Management reports beneficial ownership of 5,330,776 shares of Common Stock, representing 11.5% of the class as of 03/31/2026. The filing amends prior disclosures and notes that T. Rowe Price Small-Cap Value Fund holds 2,839,254 shares (6.1%).